Janus Henderson Investors — Funding Activity & Portfolio Companies

Activity in this selectionSeries C+

Janus Henderson Investors is an asset manager with specialist healthcare investing capabilities, including a biotechnology strategy that invests in both public and private companies.

Its Biotechnology Innovation strategy uses long-term, research-intensive analysis across the biotech landscape. The healthcare team evaluates businesses addressing unmet medical needs and technologies intended to improve the efficiency and cost of care.

The biotechnology strategy combines long investments with short selling in its portfolio construction. Private-company investment is part of this specialist asset-management activity, alongside the firm’s broader range of investment strategies.

Sources

Rounds participated in: 8
Confirmed lead rounds: 0
New companies: 8
Funding in participating rounds: $2.3B

By stage

Series C+8

By primary sector

Biotech5

Climate tech1

Healthtech1

Space tech1

By country

United States6

United Kingdom1

Rounds

8 in this selection

Oct 15

OMass Therapeutics

OMass Therapeutics develops small-molecule medicines for endocrine and immune diseases using a platform that measures drug targets in their biological surroundings.

$310MSeries C

Participant

Sep 9

Encoded Therapeutics Inc.

Encoded develops precision gene therapies for neurological disorders, led by ETX101, a gene-regulation therapy for people with SCN1A-positive Dravet syndrome.

$275MSeries F

Participant

Aug 12

FORM ENERGY

Long-duration iron-air batteries designed to store electricity for multi-day grid needs.

$750MSeries G

Participant

Aug 10

Epicrispr Biotechnologies

Develops programmable epigenetic medicines to treat genetic diseases like FSHD

$90MSeries C

Role not disclosed